ErbB signaling and cell cycle pathways associated with trastuzumab deruxtecan resistance in HER2-positive metastatic breast cancer: a case report.

ABSTRACT:

Background

Trastuzumab deruxtecan (T-DXd) significantly improves human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) outcomes. However, understanding of resistance mechanisms to T-DXd remains limited. Here, we present a case of a luminal B, HER2-positive MBC who displayed a partial response to T-DXd following five lines of prior HER2-targeted therapy but developed acquired resistance after 14 months of treatment. Organoid drug screening identified the potential strategy to overcome T-DXd resistance. Next-generation sequencing (NGS) of 550 cancer-associated genes was performed prior to T-DXd administration, and repeated after the emergence of T-DXd resistance.

Case description

We present a case of a luminal B, HER2-positive MBC. T-DXd was a

SUBMITTER: Gao HF 

PROVIDER: S-EPMC12593035 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature